Latest Headlines

Online Exclusive

OxyContin Maker Stops Promoting Opioids

Purdue, the manufacturer of OxyContin, cut its sales forces in half and will stop promoting opioids to physicians. Its sales representatives will focus on...

CDC Programs at Risk

Funding for the Centers for Disease Control and Prevention’s (CDC) public health programs have been steadily scaled back by Congress. When the Tax Cuts...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

video

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD...

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
video

Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also...
video

Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab...

Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response...
video

James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma

Dr. Kochenderfer reports "very exciting" results from bb121, a new BCMA-targeting CAR T-cell therapy for treating patients with heavily pretreated myeloma, trending towards less...

On Location

A Preview of ASH’s Venous Thromboembolism Clinical Practice Guidelines

In November 2015, the American Society of Hematology (ASH) and the McMaster University GRADE Center...

Newly Approved Drugs for AML: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting,...

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) have a higher risk of...

Feeding the Fire: CHIP and Inflammation

Clonal hematopoiesis of indeterminate potential (CHIP), known as a “premalignant” state in the blood critical...

Treating MRD With Azacitidine in Patients With High-Risk AML and MDS

For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,460FollowersFollow
5,198SubscribersSubscribe

Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint

The Janus kinase (JAK) inhibitor ruxolitinib is the only treatment approved by the U.S. Food and Drug Administration for patients with myelofibrosis (MF), and...

Can R-CHOP Plus Bortezomib Improve Outcomes in Patients With Non-GCB DLBCL?

In patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), adding the proteasome inhibitor bortezomib to standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) did...

Adding Pharmacomechanical Thrombolysis to Anticoagulation Does Not Improve Outcomes in Proximal DVT

The objective of pharmacomechanical thrombolysis, or the delivery of a fibrinolytic drug into the thrombus with concomitant thrombus aspiration, is to diminish the thrombus...

Is Oral Edoxaban an Alternative to Standard Anticoagulation in Cancer-Associated VTE?

Low-molecular-weight heparin is the standard, guideline-recommended anticoagulation therapy for patients with cancer and venous thromboembolism (VTE), but the daily subcutaneous injections can be burdensome....

Understanding Bone Disease and Fractures in Patients With MGUS

Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...